Explore the therapeutic effect and clinical application of imatinib/Gleevec

Since its advent, Imatinib/Gleevec (Imatinib) has made great achievements in the field of tumor treatment, especially in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST), showing remarkable efficacy. As a first-generation tyrosine kinase inhibitor (TKI), imatinib not only improves patient survival rates, but also changes the treatment landscape of these malignancies.

Chronic myeloid leukemia (CML) is one of the earliest and most common indications for imatinib. The increase in leukocytes in CML patients is mainly caused by the BCR-ABL fusion gene. The tyrosine kinase produced by this gene stimulates the disordered proliferation of white blood cells. By specifically inhibiting the activity of BCR-ABL tyrosine kinase, imatinib effectively prevents the proliferation of CML cells and significantly improves the survival rate of patients. Long-term follow-up data show that CML patients treated with imatinib, especially those in the chronic phase, have greatly prolonged survival. Especially in initial treatment, imatinib has demonstrated very high complete molecular response and clinical response rates, making it the standard choice for CML treatment.

In addition toCML, imatinib is also widely used in the treatment of gastrointestinal stromal tumors (GIST). GIST is a rare cancer that forms in mesenchymal cells and is often caused by mutations in the c-kit gene. Imatinib effectively slows tumor growth by inhibiting the activity of c-kit receptor tyrosine kinase. Studies have shown that imatinib can not only significantly improve the prognosis of GIST patients, but also significantly shrink the tumors of many advanced patients, and even enable some patients to achieve complete remission.

In some other indications, imatinib has also achieved remarkable results. For example, in its application in acute lymphoblastic leukemia (ALL), imatinib can effectively control BCR-ABL-positive ALL, especially in relapsed or drug-resistant patients. In addition, imatinib has also shown certain therapeutic potential in areas such as systemic sclerosis and skin tumors.

Reference materials:https://www.gleevec.com/